Abiomed's Stock Gains Following Positive Q3, Revised Guidance

Loading...
Loading...
Shares of
ABIOMED, Inc.ABMD
were trading higher by 4 percent early Thursday morning after the company reported its
third quarter results
. Abiomed said that it earned $0.23 per share in the third quarter on revenue of $85.79 million. Wall Street analysts were expecting the company to earn $0.15 per share on revenue of $80 million. Income from operations rose to $17.5 million during the quarter from $13.7 million a year ago. The company noted that the installed base for its Impella 2.5 heart pumps grew by an additional 20 hospitals, bringing its total count to 1,020 sites. In addition, 49 new hospitals purchased Impella CP, bringing the total number to 788 sites with Impella CP heart pumps. Looking forward to the full fiscal year, Abiomed raised its sales outlook from $305 million to $315 million to $326 million - exceeding the $314.7 million Wall Street analysts were expecting. "I am proud of our discipline and execution that we have demonstrated in achieving this early phase of success. We are operationally prepared with our sector expertise to take advantage of this unique organic opportunity," said Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed. "Abiomed is revolutionizing the treatment for heart failure by focusing exclusively on the heart muscle and with new indications, new geographies and new products on the horizon; the Impella platform has a long runway for growth."
Loading...
Loading...
Posted In: EarningsNewsGuidanceMoversAbiomedHeart PumpsImpella 2.5Impella CPMichael R. Minogue
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...